What may be possible for people living with MDR HIV‍-‍‍‍1?

For people living with multidrug-resistant (MDR) HIV-1, there may come a time when they need a change in regimen.1

RUKOBIA is a first-in-class attachment inhibitor specifically developed for people living with MDR HIV-1.

Explore a range of people living with MDR HIV-1 who may benefit from RUKOBIA

ARV=antiretroviral; HIV-1=human immunodeficiency virus type-1. 

The many faces of people living with MDR HIV-12-5

People living with MDR HIV-1 are a diverse group. Each has a unique journey but shares similar needs for:

  • Durable virologic suppression
  • CD4+ T-cell recovery
  • Well-tolerated ARV options with a manageable drug interaction profile
Images are not real patients. Profiles are adapted from BRIGHTE study participant characteristics.
65-year-old
Diagnosed 23 years ago
People living with MDR HIV-1 may be long-term survivors who are living with the prospect of running out of treatment options.
49-year-old
Diagnosed 20 years ago
People living with MDR HIV-1 may be concerned about ongoing viremia and the associated health risks.​ 1,7-9
29-year-old
Diagnosed 15 years ago
People living with MDR HIV-1 may feel that they have to manage the side effects that come with their ARV options.​ 6
59-year-old
Diagnosed 27 years ago
People living with MDR HIV-1 may need an ARV option with a different drug-drug interaction profile.​ 6
42-year-old
Diagnosed 20 years ago
People living with MDR HIV-1 may need another ARV option that works with their current oral dosing schedule.

Some people living with MDR HIV-1 are failing their current ARV regimen due to resistance, intolerance, or safety considerations and are in need of viable ARV options.1 Hear the unique experiences and treatment journeys of these people living with HIV-1 (PLWH).

Stories of People Living With MDR HIV-1

James

Listen as James, a heavily treatment-experienced (HTE) patient living with HIV-1, discusses his experience beginning with accepting his diagnosis to now adhering to his treatment.

 

James, living with HIV. Individual results may vary. 

Compensated by ViiV Healthcare.

DENNIS

Dennis shares his experience living with HIV and taking RUKOBIA as part of his HIV-1 treatment regimen.

 

Dennis, living with HIV and taking RUKOBIA. Individual results may vary.
Compensated by ViiV Healthcare.

References:

  1. Ackerman P, Thompson M, Molina JM, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS. 2021;35(7):1061-1072.
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated September 21, 2022. Accessed November 7, 2022. https://clinicalinfo.hiv.gov/sites/default/files/
    guidelines/documents/adultadolescent
    -arv/guidelines-adult-adolescent-arv.pdf
  3. European AIDS Clinical Society. Guidelines version 10.0: November 2019. Accessed February 1, 2020. https://www.eacsociety.org/files/
    2019_guidelines-10.0_final.pdf
  4. Henegar C, Vannappagari V, Viswanathan S, DeKoven M, Clark A, Ackerman P, et al. Identifying heavily treatment-experienced patients in a large administrative claims database. [Abstract MOPEB236] 10th IAS Conference on HIV Science (IAS); Mexico, City, Mexico, 21–24 July 2019.
  5. Pelchen-Matthews A, Ryom L, Borges AH, Edwards S, Duvivier C, Stephan C, et al. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. AIDS. 2018; 32:2405–2416.
  6. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):740-751.
  7. Pelchen-Matthews A, Borges AH, Reekie J, et al. Prevalence and outcomes for heavily treatment-experienced individuals living with human immunodeficiency virus in a European cohort. J Acquir Immune Defic Syndr. 2021;87(2):806-817.
  8. Achhra A, Amin J, Law M, et al. Immunodeficiency and the risk of serious clinical endpoints in a well-studied cohort of treated HIV-infected patients. AIDS. 2010;24(12):1877-1886.
  9. Engsig F, Zangerle R, Katsarou O, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014;58(9):1312-1321.

 

References:

  1. Ackerman P, Thompson M, Molina JM, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS. 2021;35(7):1061-1072.
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated September 21, 2022. Accessed November 7, 2022. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adultadolescent-arv/guidelines-adult-adolescent-arv.pdf
  3. European AIDS Clinical Society. Guidelines version 10.0: November 2019. Accessed February 1, 2020. https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf
  4. Henegar C, Vannappagari V, Viswanathan S, DeKoven M, Clark A, Ackerman P, et al. Identifying heavily treatment-experienced patients in a large administrative claims database. [Abstract MOPEB236] 10th IAS Conference on HIV Science (IAS); Mexico, City, Mexico, 21–24 July 2019.
  5. Pelchen-Matthews A, Ryom L, Borges AH, Edwards S, Duvivier C, Stephan C, et al. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. AIDS. 2018; 32:2405–2416.
  6. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):740-751.
  7. Pelchen-Matthews A, Borges AH, Reekie J, et al. Prevalence and outcomes for heavily treatment-experienced individuals living with human immunodeficiency virus in a European cohort. J Acquir Immune Defic Syndr. 2021;87(2):806-817.
  8. Achhra A, Amin J, Law M, et al. Immunodeficiency and the risk of serious clinical endpoints in a well-studied cohort of treated HIV-infected patients. AIDS. 2010;24(12):1877-1886.
  9. Engsig F, Zangerle R, Katsarou O, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014;58(9):1312-1321.

FSTWCNT220030